Çalışma Alanları
- Sağlık Bilimleri Temel Alanı
- Hematoloji (İç Hastalıkları)
- Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG), 2024
- Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study, 2024
- Transcriptome analysis of beta-catenin-related genes in CD34+ haematopoietic stem and progenitor cells from patients with AML, 2024
- A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma, 2024
- Current Landscape of iPSC Haplobanks, 2024
- A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma, 2024
- Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)., 2024
- Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis, 2024
- Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment, 2024
- Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases, 2024
- In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide, 2024
- Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison, 2024
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, 2024
- In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT, 2024
- Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells, 2024
- Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients, 2024
- Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group, 2023
- Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation, 2023
- Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT, 2023
- Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center, 2023
- Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network, 2023
- Upfront autologous transplantation still improving outcomes in patients with multiple myeloma, 2023
- Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome, 2023
- Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study, 2023
- HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma, 2023
- An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT, 2023
- A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset, 2023
- Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data, 2023
- Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT, 2023
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial, 2023
- Werner helicase is required for proliferation and DNA damage repair in multiple myeloma, 2022
- Upfront autologous transplantation still improving outcomes in patients with multiple myeloma, 2022
- First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey, 2022
- ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma, 2022
- Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper, 2022
- Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?, 2022
- Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma, 2022
- Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA, 2022
- Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial, 2022
- Manual Versus Automated Volume Reduction of Cord Blood, 2022
- Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT, 2022
- Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT, 2022
- Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis, 2022
- The efficacy and safety of second allogeneic hematopoietic stem cell transplantation., 2022
- Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia, 2022
- Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies, 2022
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study, 2022
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics, 2022
- Health\u2010related quality of life in patients with\n <scp>light chain<\/scp>\n amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone\u2009±\u2009daratumumab: Results from the\n <scp>ANDROMEDA<\/scp>\n study, 2022
- Extramedullary disease in multiple myeloma: a systematic literature review, 2022
- Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019, 2022
- Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease, 2022
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study, 2022
- A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity, 2021
- Highlighting the Prognostic Importance of Measurable Residual Disease Amongst Acute Myeloid Leukemia Risk Factors, 2021
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome, 2021
- Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, 2021
- Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications, 2021
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study, 2021
- Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study, 2021
- Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma, 2021
- Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT), 2021
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis, 2021
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network, 2021
- Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma, 2021
- Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group, 2021
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide\u2010pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics, 2021
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2021
- Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review, 2021
- Health\u2010related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial, 2021
- Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party, 2021
- Expert review on soft\u2010tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations, 2021
- A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT, 2021
- Prognostic impact of early\u2010versus\u2010late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT, 2021
- HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA, 2021
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study, 2021
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021
- Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma, 2021
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021
- CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma, 2021
- Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors, 2021
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome., 2020
- A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT, 2020
- Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience., 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Efficacy and safety of weekly carfilzomib (70 mg/m sup2/sup ), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies/title, 2020
- Efficacy and safety of weekly carfilzomib (70\u2009mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies, 2020
- Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM), 2020
- Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT), 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data, 2020
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Drug Targeting of Genomic Instability in Multiple Myeloma, 2020
- Isatuximab for the treatment of relapsed/refractory multiple myeloma, 2020
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study, 2020
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial, 2020
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study, 2020
- Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice, 2020
- Prognostic scoring system after transplantation in myeloma: predicting early relapse, 2020
- Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation, 2020
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2020
- Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma, 2020
- Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma, 2020
- Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation, 2020
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020
- Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS), 2020
- Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT, 2020
- Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma, 2020
- Our Treatment Approach to Hairy Cell Leukemia, 2020
- Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells, 2019
- A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma, 2019
- PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma, 2019
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome, 2019
- Insights on Multiple Myeloma Treatment Strategies, 2019
- Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies, 2019
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial, 2019
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial, 2019
- A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis, 2019
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients, 2019
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study, 2019
- Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide and/or Bortezomib Containing Regimens, 2019
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019, 2019
- Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice, 2019
- Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma, 2019
- Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center, 2018
- Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center, 2018
- The outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4T cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect, 2018
- The impact of 17 B estradiol level variations on blood lymphocyte counts among healthy females, 2018
- Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience, 2018
- title Daratumumab plus bortezomib and dexamethasone iversus/i bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR/title, 2018
- Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience, 2018
- The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females, 2018
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies, 2018
- KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?, 2018
- KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation, 2018
- Kronik Lenfositik Lösemi’de Tanı Anında Hipogammaglobulinemi Sağkalım ve Enfeksiyon Riski Üzerine Etklili Midir?, 2018
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients., 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, 2018
- A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis, 2018
- The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females, 2018
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipientss?, 2018
- Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- The safety of bortezomib for the treatment of multiple myeloma, 2018
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network, 2018
- Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Total Blood Lymphocyte Count Alteration During and after Pregnancy, 2017
- Subsequent malignancies after allogeneic hematopoietic stem cell transplantation, 2017
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma, 2017
- Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study, 2017
- Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment, 2017
- Extracorporeal photochemotherapy in mycosis fungoides, 2017
- Heparin enhances CD34 content of stem cells collected following G-CSF /- chemotherapy, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells, 2017
- Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study, 2017
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and ipost-hoc/i analyses on progression-free survival and tumour growth/title, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- A single center experience with two decades of follow-up on patients with hairy cell leukemia., 2017
- Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia., 2017
- A single center experience with two decades of follow-up on patients with hairy cell leukemia., 2017
- Large unstained cell percentage as a predictor ofefficacious peripheral stem cell mobilization in autologousstem cell transplantation, 2017
- Evaluating peritransplant albumin decline as a predictor ofacute graft versus host disease, 2017
- Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible totransplant safely?, 2017
- P529HLA C1/C1 homozygosity decreases relapse rate afterallogeneic hematopoietic stem cell transplantation(Allo-HSCT) in acute myeloid leukemia (AML) patients, 2017
- A Biosimiliar G-CSF filgrastim is as effective as a referencedrug however itis not as cost effectiveas it supposed to beand by the way no impact on the health care system, 2017
- Peripheral blood stem cell mobilization and collectionfrom elderly patients (≥65 years) with multiple myeloma: Asingle center experience, 2017
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study, 2017
- Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial, 2017
- THE IMPACT OF 17Β ESTRADIOL LEVEL VARIATIONS ON BLOOD LYMPHOCYTE COUNTS AMONG HEALTHY FEMALES, 2017
- extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease, 2017
- A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, 2016
- Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4., 2016
- Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial)., 2016
- Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study., 2016
- Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants, 2016
- How to Improve Cord Blood Engraftment, 2016
- Editorial How to Improve Cord Blood Transplantation By Enhancing Cell Counts or Engraftment, 2016
- Flow Cytometrıc Aldehyde Dehydrogenase Aldh Assay Enables A Fast And Accurate Human Umblical Cord Blood Hematopoietic Stem Cell Assessment, 2016
- Phase 2 study of tabalumab a human anti B cell activating factor antibody with bortezomib and dexamethasone in patients with previously treated multiple myeloma, 2016
- Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone the PANORAMA 1 trial a randomised placebo controlled phase 3 trial, 2016
- HLA polymorphism and risk of multiple myeloma, 2016
- Daratumumab Bortezomib and Dexamethasone for Multiple Myeloma, 2016
- Central nervous system involvement by multiple myeloma A multi institutional retrospective study of 172 patients in daily clinical practice, 2016
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma outcomes by prior treatment, 2016
- A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker, 2016
- Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation, 2015
- Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups, 2015
- Effects of in utero cord blood collection on post-cesarean hemoglobin levels, 2015
- Impact of “Killer Immunoglobulin-Like Receptor /Ligand” Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival, 2015
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, 2015
- Insight into human protease activated receptor-1 as anticancer target by molecular modelling, 2015
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, 2015
- Panobinostat a novel pan deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma, 2015
- Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma results from the EBMT NMAM2000 prospective trial, 2015
- Antilymphocyte Thymocyte Globulin for the Treatment of Steroid Refractory Acute Graft Versus Host Disease 20 Year Experience at a Single Center, 2015
- Analysis of Final Data from the Multinational Non Interventional Observational Emmos Study NCT01241396 in Patients Pts with Multiple Myeloma MM in Real World Clinical Practice, 2015
- Retrospective matched pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma, 2015
- Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values, 2014
- Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation, 2014
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, 2014
- High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial, 2014
- Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study, 2014
- Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee, 2014
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial, 2014
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, 2014
- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma, 2014
- HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex™ technology, 2014
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma a multicentre randomised double blind phase 3 trial, 2014
- Hemorrhagic Cystitis as a Complication of Bone Marrow Transplantation, 2013
- Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma, 2013
- Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study, 2013
- Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease, 2013
- Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma, 2012
- Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients, 2012
- Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study., 2012
- IMWG consensus on maintenance therapy in multiple myeloma, 2012
- Management of treatment-emergent peripheral neuropathy in multiple myeloma, 2012
- Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells, 2012
- Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials, 2012
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma, 2012
- Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective, 2011
- Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up, 2011
- Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial, 2011
- An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells, 2011
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement, 2011
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group, 2011
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN), 2011
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials, 2011
- The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans, 2011
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3, 2011
- Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic?, 2011
- Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective, 2010
- Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial, 2010
- Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations, 2010
- Lack of Prognostic Value of CD34 in Adult AML, 2009
- Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF, 2009
- Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival, 2009
- International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma, 2009
- Vitiligo after Hematopoietic Cell Transplantation: Six Cases and Review of the Literature, 2008
- Familial Multiple Myeloma Associated with Disorders of Chronic Inflammation: First Report from Turkey, 2008
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group, 2008
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders, 2008
- High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis, 2007
- International uniform response criteria for multiple myeloma, 2006
- Expression of IFITM1 in chronic myeloid leukemia patients, 2005
- Filgrastim-Mobilized Peripheral Blood Progenitor Cells Versus Bone Marrow Transplantation For Treating Leukemia: 3-Year Results From The EBMT Randomized Trial, 2005
- HLA A B C DR haplotypes linkeage and frequencies observed inAnkara University Turkey a report from Tran, 2005
- Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease, 2004
- Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow, 2003
- Differences between graft product and donor side effects following bone marrow or stem cell donation, 2003
- CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation, 2001
- Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914), 2001
- The effect of G-CSF on lymphocyte subsets and CD34 cells in allogeneic stem cell transplantation, 2001
- Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM), 2001
- Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation, 2001
- CD41 and CD42 hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation, 2001
- Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia, 2001
- Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF, 2000
- Thrombopoietic Cytokines in Patients with Iron Deficiency Anemia with or without Thrombocytosis, 2000
- Chronic graft-versus-host disease complicated by membranous glomerulonephritis, 1999
- The impact of the CD34 cell dose on engraftment in allogeneic peripheral blood stem cell transplantation, 1999
- Incidence of Tuberculosis after bone marrow transplantation in a single center from Turkey, 1998
- Randomised unicenter trial for comparison of three regimens inde novo adult acute nonlymphoblastic leukaemia, 1998
- HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia, 1997
- Hepatitis B virus infection in allogeneic bone marrow transplantation, 1997
- A RAPID DRUG SENSITIVITY ASSAY FOR NEOPLASMATIC CELLS, 1988
- Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study, 2024
- Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study, 2024
- Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial, 2024
- Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide, 2024
- Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM), 2024
- Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM), 2024
- Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis,
- Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd), 2024
- Analysis of Beta-catenin Mutations in Acute Myeloid Leukemia., 2017
- External Valıdatıon Of Three Exıstıng Early Myeloma Relapse Scores (By Ebmt, Cıbmtr, And Gımema) In A Sıngle Center Shows Major Dıfferences, 2023
- Otoimmün Hemolitik Anemi ve T-LGL Birlikteliği Nadir Bir Olgu, 2023
- Hemofili A ve Multipl Miyelom Tanılı Hastada Otolog Periferik Kök Hücre Mobilizasyonu: Olgu Sunumu, 2023
- Kök hücre toplamada Plerixafor' un yeri: Kemoterapisiz de olur mu?, 2023
- Myelofibroziste allojenik hematopoetik kök hücre nakli sonuçları: tek merkez deneyimi, 2023
- Siklofosfamid ile Mobilizasyonunun Multipl Miyelom Hastalarında Nakil Sonuçlarına Etkileri, 2023
- MULTİPL MİYELOMDA KILLER IMMUNOGLOBULIN-LIKERESEPTÖRLERİ (KIR) VE LİGANDLARI İLE HLA- GRUP C1 VEC2’NİN SIKLIĞI, 2017
- KIR2DS4’ÜN MİYELOM PLAZMA HÜCRELERİNE KARŞIOTOLOG VEYA KORDON KANI DOĞAL ÖLDÜRÜCÜ HÜCREARACILIKLI TOKSİSİTEDE ROLÜ, 2018
- İndüksiyon Mu Hazırlama Rejimi Mi Daha Önemli? İndüksiyon Sonrası Kalıntı Hastalığın Saptanamaması Bir Prognostik Gösterge Olabilir, 2018
- Multipl miyelomda Killer Immunoglobulin like Reseptörleri (KIR) ve ligandları ile HLA- Grup C1 ve C2'nin sıklığı, 2017
- Decreased Multiple Myeloma Viability of Malignant Plasma Cells by Inhibition of Werner Helicase, 2017
- OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ?, 2017
- ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASI AKUT MYELOİD LÖSEMİ NÜKSÜNÜN YÖNETİMİ VE PROGNOZU, 2018
- YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ, 2019
- Evaluating response to treatment in patients with EMD, 2022
- Post-authorization safety of lenalidomide+dexamethasone in patients with multiple myeloma in Turkey, 2022
- Current status & updates in the management of AL amyloidosis, 2022
- The potential of studying circulating plasma cells in multiple myeloma, 2022
- Updates of ongoing EMN studies, 2022
- Quadruplet therapy with and without autoHSCT in NDMM, 2022
- Extramedullary Dısease, 2022
- Plasma Cell Disorders subcommittee Project Presentations, 2022
- Multipl Miyelom ve yeni nesil tedavi seçenekleri, 2022
- Extramedullary myeloma, 2022
- Special Lectures on Extramedullary Disease, 2022
- Selecting frontline treatments strategies & monitoring patients with multiple myeloma, 2022
- Preventing and managing post-transplant complications in multiple myeloma, 2022
- Risk assessment & transplant decisions in multiple myeloma, 2022
- The value of MRD as a prognostic tool in myeloma, 2022
- An insight into familial myeloma, 2022
- Multiple myeloma, 2022
- Plasma cell disorders subcommittee projects presentation, 2022
- A Focus on Multiple Myeloma, 2022
- Contemporary Management of AL Amyloidosis, 2022
- MRD to drive therapy, 2022
- Efficacy and outcome of modern standard treatment vs. ASCT in newly diagnosed multiple myeloma patients, 2022
- EBMT scoring system for early relapse after auto-HCT in MM Patients, 2022
- Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial, 2022
- Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome, 2022
- Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience, 2022
- Graft Versus Host Hastalığı Profilaksisinde ATG Ve Post CY Kullanımının Nakil Sonuçlarına Etkisi: Tek Merkez Deneyimi, 2022
- İkinci Allojeneik Kök Hücre Nakli: Gerçek Yaşam Verisi, 2022
- Amniyon Sıvısının, VPA İle Ekspande Hematopoietik Kök Hücre Nakli Sonrası Engrafmana Etkisinin İn Vivo Araştırılması, 2022
- OKHN Sonrası İlk 12 Ayda Nüksü Belirlemede Gımema Ve CIBMTR Skorlama Yaklaşımlarının Bağımsız Hasta Grubunda Validasyonu, 2022
- Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19), 2022
- Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study, 2022
- Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021, 2022
- Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies, 2022
- 64th ASH Annual Meeting & Exposition, 2022
- MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma, 2022
- The efficacy and safety of second allogeneic hematopoietic stem cell transplantation, 2022
- Ibrutınıb As A Promısıng Treatment For Waldenström Macroglobulınemıa, 2022
- Carfılzomıb, Lenalıdomıde, Dexamethasone Followed By A Second Auto-Hct Is An Effectıve Strategy In Fırst Relapse Multıple Myeloma: A Study Of The Chronıc Malıgnancıes Workıng Party Of EBMT, 2022
- Daratumumab Plus Bortezomıb And Dexamethasone Versus Bortezomıb And Dexamethasone Alone In Patıents Wıth Prevıously Treated Multıple Myeloma: Overall Survıval Results From The Phase 3 Castor Trıal, 2022
- Response And Vaccınatıon Status Or Lack Of Immunoparesıs Are Assocıated Wıth Better Outcome Followıng Covıd-19 Infectıon Among Patıents Dıagnosed Wıth Multıple Myeloma: A Sıngle Center Experıence On 110 Patıents, 2022
- Pomalıdomıde, Bortezomıb, And Dexamethasone In Lenalıdomıde–Pretreated Multıple Myeloma: A Subanalysıs Of Optımısmm By Fraılty, 2022
- Ex Vivo Epigenetic Modification with Valproic Acid (VPA) Plus Nicotinamide (NAM) Results in Expansion of Umbilical Cord Blood Hematopoietic Progenitors Leading to Faster Engraftment and Chimerism in In Vivo Mouse Xenograft Model, 2022
- Phase 3 Study of Belantamab Mafodotin with Pomalidomide (Pom) + Dexamethasone (Dex) vs Bortezomib + Pom/Dex in Relapsed/Refractory Myeloma, 2022
- Daratumumab(DARA)+Bortezomib/Cyclophosphamide/Dexamethasone (D-VCd) in Newly Diagnosed AL Amyloidosis: 18-month Landmark Analysis of ANDROMEDA, 2022
- Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone in Patients With Previously Treated Multiple Myeloma: Overall Survival Results From the Phase 3 CASTOR Trial, 2022
- An Early Post-Transplant Relapse Predıctıon Score In Multıple Myeloma Patıents: A Large Cohort Study From Chronıc Malıgnancıes Workıng Party Of EBMT, 2022
- Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty, 2022
- EX VIVO EXPANSION OF HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS (HSCS) WITH VALPROIC ACID (VPA) OR NEUROTROPHIC FACTOR (NTF), 2017
- Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience, 2018
- KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines, 2018
- The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4(+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect, 2018
- Carfilzomib ve Pomalidomid Etkinliğinin Retrospektif Değerlendirilmesi: Ankara Üniversitesi Deneyimi, 2017
- Ankara Üniversitesi Tıp Fakültesi Multiple Myelom Elotuzumab ve İmmünmodulatuar İlaç Tedavi Deneyimi, 2017
- İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi, 2017
- Clonal Plasma Cell Detection by High Sensitive Flow Cytometry in Aphaeresis Product is Poor Prognostıc and not Increased by Use of Plerixafor Alone, 2019
- Evaluating peritransplant albumin decline as a predictor of acute graft versus host disease, 2017
- Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation, 2017
- Therapeutic Thrombocytapheresis: Higher Platelet Counts Should Matter, 2016
- Heparin Enhances CD34 Content of Stem Cells Collected Following G-CSF +/- Chemotherapy, 2017
- A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance, 2018
- A Preliminary Analysis of Inherited Immune Checkpoint Control in Multiple Myeloma: Relative Frequency of Inhibitory or Activating Type Killer Immunoglobulin like Receptors and Their Cognate Ligands HLA-C1 and -C2, 2017
- Residual Clonal Plasma Cells Detected by Flow Cytometry at 10-4 Level within Autologous Stem Cell Grafts is Associated with Significantly Less Overall Survival, 2018
- Multipl Miyelom Olgularında Otolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları, 2019
- Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler Mi?, 2019
- The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence, 2019
- Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ?, 2019
- Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation, 2019
- Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset, 2021
- Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation, 2021
- Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience, 2020
- A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm, 2020
- Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?, 2019
- Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation, 2019
- Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis, 2020
- KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells, 2020
- Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow, 2020
- Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma, 2018
- A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R), 2019
- Is post-transplant albumin a predictor of early transplant complications?, 2018
- Ruxolitinib in steroid refractory GVHD treatment: single center experience, 2018
- Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen, 2018
- Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma, 2018
- Results Of A Sıngle Center Experıence: An Attempt To Augment Condıtıonıng Regımen In Fırst Autologous Stem Cell Transplantatıon, 2019
- Is mobilization with chemotherapy effect response in the multiple myeloma?, 2019
- Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions, 2019
- Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag, 2020
- Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa?, 2020
- The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon, 2020
- Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML), 2020
- Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data, 2019
- Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?, 2019
- Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis, 2019
- Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs, 2019
- Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic, 2021
- KILLER IMMUNOGLOBULIN LIKE HAPLOTYPE BB IS OBSERVED MORE FREQUENTLY AMONG MYELOMA CASES COMPARED TO HEALTHY CONTROLS, 2021
- CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION, 2019
- PRE-TRANSPLANT HEMOGLOBIN AND SERUM CREATININE LEVELS CORRELATE WITH PROGRESSION FREE SURVIVAL IN MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION, 2019
- LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER, 2019
- CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?, 2019
- POSTTRANSPLANT LENFOSİTOZ ÖNEMLİ BİR PARAMETRE MİDİR?, 2019
- AKUT MİYELOİD LÖSEMİDE NAKİL ÖNCESİ MİNİMAL KALINTI HASTALIK DİĞER RİSK FAKTÖRLERİNDEN DAHA ÖNEMLİ MİDİR?, 2019
- Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi?, 2021
- ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ, 2018
- Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu, 2018
- NGS TÜM SEÇENEKLERİ TÜKETMİŞ NÜKS VE DİRENÇLİ MM HASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADA REHBERLİK EDEBİLİR Mİ?, 2019
- Evaluation of chemokine reseptor 4 expression by 68Ga Pentixafor PET/CT in patients with multiple myeloma, 2018
- Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization, 2017
- A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be, 2017
- Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler, 2017
- Evaluation of chemocine reseptor 4 expression by 68Ga pentixafor PET/CT in patients with multiple myeloma, 2018
- Multiple myeloma - Frontline therapy, 2021
- The management of R/R multiple myeloma patients, 2021
- DM6-1 Response in Multiple Myeloma, 2021
- Post-Induction Undetectable Minimal Residual Disease at 10-5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk, 2021
- Ülkemiz Ailesel Miyelom Olgularında Saptanan Varyantlar :RAG2, CBL, APC ve PTCH1 Genleri, 2021
- Hastalık biyolojisinde güncel gelişmeler, 2021
- Kordon Kanı Kök Hücre ve Natural Killer Hücre Ekspansiyonu, 2021
- Plasma cell disorders subcommittee projects presentation, 2021
- IMID’LERDE ARTAN GÜÇ: POMALIDOMID, 2021
- Treatment with BiTEs: Is it the new standard for penta-refractory patients?, 2021
- Response in Multiple Myeloma, 2021
- Therapy of elderly patients, 2021
- Multiple Miyelom, 2021
- Scoring system for Auto-HCT: feasibility in MM patients, 2021
- Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch–Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network, 2021
- Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease, 2021
- Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study, 2021
- Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the Cmwp-EBMT, 2021
- Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study, 2021
- A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party, 2021
- Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE), 2021
- Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO., 2021
- Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial, 2021
- Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma, 2021
- The Role Of Upfront Autotransplantatıon And Consolıdatıon Therapy In Newly Dıagnosed Multıple Myeloma (Ndmm): Fınal Analysıs Of The Randomızed Phase 3 Emn02/Ho95 Study, 2021
- Immunoglobulin V(D) J Recombination, Protein Ubiquitination, Cell Adhesion and Sonic Hedgehog Gene Variants are detected among familial Multiple Myeloma subjects following whole exome sequencing, 2021
- Trends in Autologous Stem Cell Mobilisation Practices in Myeloma Patients in Ebmt Centers Between 2008 And 2017, 2021
- Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP, 2021
- COVID-19 Pandemisinde Allojeneik Hematopoetik Hücrelerin Kriyoprezervasyonu, 2021
- Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients, 2021
- Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM), 2021
- Multipl Miyelomda Otolog Priferik Kök Hücre Nakli Sonrası Erken Nüksü Belirlemede CIBMTR, ISS ve R-ISS Skorlama Sistemlerinin Karşılaştırılması, 2021
- SUBCUTANEOUS DARATUMUMAB ± BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE in patients with newly diagnosed light chain amyloidosis: Updated results from the phase 3 andromeda study, 2021
- Molecular Alterations Obtained by High Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targetted Therapies, 2021
- Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO., 2021
- Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM)., 2021
- Assocıatıon Of Reduced Absolute İflc And Dflc Wıth Prolonged Major Organ Deterıoratıon Progressıon-Free Survıval In Patıents Wıth Newly Dıagnosed Al Amyloıdosıs Receıvıng VCD Wıth Or Wıthout Daratumumab: Results From Andromeda, 2021
- Melfelan Hazırlık Rejimi Tek Gün Ve İki Gün Kullanımı Yan Etki Değerlendirmesi, Fark Var Mı ?, 2021
- In Vitro Semisolid Agar Veya Sıvı Kültür Koşullarında Vpa Ve Nam Gibi Küçük Moleküller Aracılığı İle Hematopoietik Kök Hücre Ekspansiyonu Kinetikleri, 2021
- Fare-İnsan Xenograft Hematopoietik Kök Hücre Nakli Modelinde Vpa Ve/Veya Nam İle Ekspande Edilmiş Hematopoietik Kök Hücrelerin Engrafman Kinetikleri, 2021
- Allojenik Kök Hücre Nakli Hastalarında Peritransplant Metronidazol Kullanımıyla Akut GVHD Riskinin İlişkisi, 2021
- Solid Organ Nakli Ve Allojenik Kök Hücre Nakli Sonrası Gelişen Post-Transplant Lenfoproliferatif Hastalık- Tek Merkez Deneyimi, 2021
- Relaps/Refrakter Hodgkin Lenfoma Hastalarında Allojenik Hematopoetik Kök Hücre Nakli: Tek Merkez Deneyimi, 2021
- Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University, 2021
- Treatment of Patients With Relapsed/Refractory Multiple Myeloma With Pomalidomide and Dexamethasone With or Without Subcutaneous Daratumumab: Patient-Reported Outcomes From APOLLO, 2021
- Large Unsatained Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation, 2017
- Heparin enhances CD34 content of stem cells collected following G-CSF +/- chemotherapy, 2018
- A Biosimiliar G-CSF filgrastim is as effective as a reference drug however it is not cost effective as supposed to be and by the way no impact on the health care system, 2017
- Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease, 2017
- Condıtıonıng Wıth Bortezomıb-Mel200 In Comparıson To Mel200 Improves Survıval Among Myeloma Patıents In≤Pr Prıor To Auto-Hct: A Study From The Cmwp Of The Ebmt, 2020
- Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95), 2020
- Post-Transplant Cyclophosphamide for Graft Vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison By Donor Type A Study from the Chronic Malignancies Working Party of the EBMT, 2020
- Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda, 2020
- Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT, 2020
- Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study, 2020
- Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Soft-Tissue Plasmacytomas: Icaria-MM Subgroup Analysis, 2020
- Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM), 2020
- Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study, 2020
- Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study, 2020
- Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized PANORAMA 3 Study, 2020
- Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies, 2020
- A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Isatuximab, Pomalidomide, and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed / Multiple Myeloma Refractory (RRMM), 2020
- Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM, 2020
- Ixazomıb Vs Placebo As Post-Inductıon Maıntenance Therapy In Newly Dıagnosed Multıple Myeloma (Ndmm) Patıents (Pts) Not Undergoıng Autologous Stem Cell Transplant (Asct): Phase 3 Tourmalıne-Mm4, 2020
- Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001, 2020
- Pomalıdomıde, Bortezomıb, Dexamethasone After 1 Prıor Lıne Of Therapy In Patıents Wıth Relapsed Or Refractory Multıple Myeloma And Renal Impaırment: Optımısmm Subanalysıs, 2020
- Isatuxımab Plus Pomalıdomıde And Dexamethasone In Patıents Wıth Relapsed/Refractory Multıple Myeloma And Soft-Tıssue Plasmacytomas: Icarıa-Mm Subgroup Analysıs, 2020
- Subcutaneous Daratumumab Cyclophosphamıde, Bortezomıb, And Dexamethasone (Cybord) In Patıents Wıth Newly Dıagnosed Lıght Chaın (Al) Amyloıdosıs: Prımary Results From The Phase 3 Andromeda Study, 2020
- Ixazomıb Vs Placebo As Post-Inductıon Maıntenance Therapy In Newly Dıagnosed Multıple Myeloma (Ndmm) Patıents (Pts) Not Undergoıng Autologous Stem Cell Transplant (Asct): Phase 3 Tourmalıne-Mm4 Trıal, 2020
- How should we position immunotherapies in the changing paradigm of myeloma treatment?, 2020
- Updates and study issues, 2020
- Extramedullary myeloma: an unmet need, 2020
- How to manage myeloma patients during a pandemic?, 2020
- COVID 19 Pandemisinde Myelom Yönetimi ve Oral Tedaviler, 2020
- Immunomodülatuar İlaçlar ve Multiple Myeloma, 2020
- COVID 19 Pandemisinde Myelomda Oral Tedaviler, 2020
- Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study., 2012
- Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Risk assessment at diagnosis and risk based therapy, 2020
- Update on multiple myeloma, 2020
- Monoclonal Antibodies in Newly Diagnosed Multiple Myeloma: New Trials and Combinations, 2020
- Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study., 2016
- TREATMENT OF MYELOMA:MAİNTENANCE STRATEGY, 2019
- Challenges and importance of long-term treatment for newly diagnosed multiple myeloma patients community-based trial data, 2019
- Double ASCT: Suitable for all patients, 2019
- The viewpoint of Scientific Groups: Part 2, 2019
- Current Immunotherapies, 2019
- Myeloma, 2019
- Relapsed myeloma, 2019
- Multiple Myeloma, 2019
- Türkiye’de erişilebilir yeni tedaviler ve klinik araştırmalar, 2019
- Multıple Myeloma ve Plazma Hücre Hastalıkları, 2019
- Multiple Myeloma - the Best Therapy for newly diagnosed patients in 2019, 2019
- A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM), 2019
- Analysis of outcomes in patients with myeloma who had a second allohct EITHER for disease relapse or graft failure: AN EBMT CMWP study, 2019
- Multiple myeloma treatment in real-world clinical practice: A focus on induction regimens prior to autologous stem cell transplantation from the prospective, multinational, non-interventional emmos study, 2019
- Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT, 2019
- A Phase 3 Randomızed, Open-Label, Multıcenter Study Of Isatuxımab, Pomalıdomıde, And Low-Dose Dexamethasone Vs Pomalıdomıde And Low-Dose Dexamethasone In Relapsed/Refractory Multıple Myeloma (Rrmm), 2019
- Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial, 2019
- Prognostic value of post-induction PET/CT in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), 2012
- RETROSPECTIVE ANALYSIS OF 149 UNSELECTED PATIENTSWITH MANTLE CELL LYMPHOMA CONFIRMS PROGNOSTICRELEVANCE OF MIPI: SINGLE CENTER EXPERIENCE, 2019
- Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients – the Diadem Study from the Chronic Malignancies Working Party of the EBMT, 2019
- Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?,
- Multiple Myelom Hastalarında Otolog Periferik Kök Hücre Nakli Esnasında Gelişen Nötropenik Ateş, 2019
- İyi Riskli Aml’de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi, 2019
- Miyelom Hastalarında Ohkhn Öncesi Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi?, 2019
- Autologous Stem Cell Transplantatıon Versus Bortezomıb-Melphalan-Prednısone For Newly Dıagnosed Multıple Myeloma Patıents: Fınal Analysıs Of The Phase 3 Emn02/Ho95 Study, 2019
- Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmede Kimerizm İle Mrd Karşılaştırılması, 2019
- Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable = Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey, 2019
- Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimimiz, 2019
- Impact of ABO mismatch on outcomes of allogeneic hematopoietic stem cell recipients: 30 years of experience with 1016 patients., 2019
- Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür Sağlayabilir mi?, 2019
- T-All Hastalarında Allojeneik Hematopoetik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi?, 2019
- KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL’DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?, 2019
- Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation., 2019
- Maternal ve Fetal Serum Örneklerinde HematopoietikSitokinler Olan Kök Hücre Faktör (Stem Cell Factor=SCF)ve Granülosit Düzeylerinin ve in vitro Etkinliklerinin Karşılaştırılmalı Analizi, 2017
- Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis, 2019
- Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/Relapsed or Refractory Multiple Myeloma, 2019
- Modulation of NK, T, B cell subpopulations by Pomalidomide predicts favorable progression-free survival (PFS): Results from a large randomized clinical trial in relapsed/refractory myeloma, 2019
- Management of adverse events (AEs) observed in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (MM), 2019
- Ex Vıvo Expansıon Of Human Umbılıcal Cord Blood Hematopoıetıc Stem Cells Wıth Valproıc Acıdor Nıcotınamıde Is Able To Accelerate Engraftment In A Nsg Mouse Transplant Model, 2019
- Effıcacy And Safety Of Daratumumab, Bortezomıb, And Dexamethasone (D-Vd) In Relapsed Or Refractory Multıple Myeloma (Rrmm): Updated Subgroup Analysıs Of Castor Based On Cytogenetıc Rısk, 2019
- Sıgnıfıcant Pom Effect On The Immune-Cellprofıles In B, T And Nk Subsets In A Large Cohortclınıcal Trıal In Relapsed/Refractory Myeloma, 2019
- 1st INTERNATIONAL HEALTH SCIENCE and LIFE CONGRESS (IHSLC 2018), 2018
- Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma, 2019
- Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017, 2019
- Protocol for an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma (INTEGRATE), 2019
- ANTI-PD-1 Treatment in a Family with Constitutional Mismatch Repair Deficiency Syndrome with Multiple Cancers from Turkey. Is Cancer Immunoprevention with Checkpoint Inhibitors HAS a Role in CASES with Homozygous Mutationis, 2019
- Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT, 2019
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies, 2018
- Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: updated subgroup analysis of CASTOR, 2019
- Maintenance Therapy with the Oral Proteasome Inhibitor Ixazomib Significantly Prolongs Progression-Free Survival Post-Autologous Stem Cell Transplantation Vs Placebo in Patients with Newly Diagnosed Multiple Myeloma: Phase 3 TOURMALINE-MM3 Trial, 2019
- Hematolojik Maligniteli Hastalarda Haploidentik Kök Hücre Nakillerinde Mezenkimal Kök Hücre Uygulaması, 2017
- İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi, 2019
- Clinical experiences from around the world, 2018
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF DARATUMUMABMONOTHERAPY FOR PATIENTS (PTS) WITH INTERMEDIATE OR HIGH-RISK SMOLDERINGMULTIPLE MYELOMA (SMM): CENTAURUS, 2018
- Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM), 2018
- Consolıdatıon Followed By Maıntenance Vs Maıntenance Alone In Newly Dıagnosed, Transplant Elıgıble Multıple Myeloma: A Randomızed Phase 3 Study Of The European Myeloma Network (Emn02/Ho95 Mm Trıal), 2018
- Daratumumab plus bortezomib-melphalan-prednisone (VMP) in elderly (≥75 y) patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE), 2018
- Addressıng Unmet Medıcal Needs In Maıntenance Treatment For Newly Dıagnosed Multıple Myeloma (NDMM): Current Treatment Landscape And Emergıng Therapeutıc Optıons, 2018
- State of the art myeloma treatment in Turkey and southeastern European countries on the Balkan peninsula, 2018
- IMiDs and proteasome inhibitors, 2018
- Newly Diagnosed Patients With Multiple Myeloma Multiple, 2018
- Optimal strategy for RRMM treatment, 2018
- Ölçülebilir kalıntı hastalık ve klinik önemi,
- Optımısmm: Phase 3 Study Of Pomalıdomıde, Bortezomıb, And Low Dose Of Dexamentasone Vs. Bortezomıb And Low Dose Of Dexamethasone In Patıents Exposed To Lenalıdomıde After Fırst Collectıon Of Multıple Myeloma, 2018
- Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial, 2018
- Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial, 2018
- Daratumumab Plus Bortezomıb-Melphalan-Prednısone (Vmp) In Elderly (≥75 Years Of Age)Patıents Wıth Newly Dıagnosed Multıple Myeloma Inelıgıble For Transplantatıon (Alcyone), 2018
- OPTIMISMM: PHASE 3 STUDY OF POMALIDOMIDE, BORTEZOMIB, AND LOW DOSE OF DEXAMENTASONE VS. BORTEZOMIB AND LOW DOSE OF DEXAMETHASONE IN PATIENTS EXPOSED TO LENALIDOMIDE AFTER FIRST COLLECTION OF MULTIPLE MYELOMA, 2018
- Fit Elderly Patients with aggressive lymphoma do not needdose reduction of conditioning regimen, 2018
- Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience, 2018
- Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience, 2018
- ANTİ-CD38 MONOKLONAL ANTİKOR TEDAVİSİ ALANMULTİPLE MYELOM HASTALARINDA ERİTROSİTTRANSFÜZYONUNA YAKLAŞIM, 2018
- Impact of Hepatitis B Core Antibody Seopositivity on theLiver Function Tests after Autologous Hematopoietic StemCell Transplantation For Multiple Myeloma, 2018
- Kır2ds4’ün Miyelom Plazma Hücrelerine Karşı Otolog Veya Kordon Kanı Doğal Öldürücü Hücre Aracılıklı Toksisitede Rolü, 2018
- Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM), 2018
- Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial, 2018
- A Cross Sectional Epidemiological and Survival Analysis of All Patients with Plasma Cell Disorders Recorded between 2011- 2017 in the Social Insurance System of Turkey, 2018
- Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients, 2018
- Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM), 2018
- Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)., 2018
- Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience, 2018
- Patıent Reported Outcomes (Pros) Of Multıple Myeloma (Mm) Patıents From The Panorama-1 Study Who Have Receıved At Least Two Prıor Regımens Includıng Bortezomıb And An Immunomodulatory Agent, 2018
- Real World Retrospectıve Analysıs Of Extramedullary Dısease From Balkan Myeloma Study Group And Barcelona Unıversıty: Clınıcal Features And Outcome, 2018
- Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM), 2018
- Impact Of Mesenchymal Stromal Cells On In Vıtro Growth Of Fresh Human Myeloma Plasma Cells And On Autologous/Cord Blood Nk Cell Medıated Cytotoxıcıty, 2018
- Real-World Data in Relapsed Refractory Myeloma Patients Treated with Pomalidomide, a Multicenter Turkish Experience, 2017
- Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma, 2017
- Phase 3 ELOQUENT-2 study: extended 4-y follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM), 2017
- ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR, 2018
- Clinical Autologous Transplantation, 2017
- Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study, 2017
- Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study, 2017
- REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH POMALIDOMIDE, A MULTICENTER TURKISH EXPERİENCE, 2017
- Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma, 2017
- Bortezomib-Based Therapy Overcomes the Adverse Impact of Renal Impairment in Transplant Eligible Patients : An Analysis of the Prospective Randomized EMN02/HO95 Study, 2017
- REAL-WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH POMALIDOMIDE , A MULTI CENTER TURKISH EZXPERIENCE, 2017
- Management and Outcome of Central Nerve System(CNS) Involvement in Acute Lymphoblastic Leukemia, 2017
- Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients, 2017
- AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: SINGLE CENTER EXPERIENCE,
- Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.,
- A single center experience with two decades of follow-up on patients with hairy cell leukemia.,
- ALLOEGENEİC HEMATOPOİETİC STEM CELL TRANSPLANTATİON İN ADVANCED AGE ADULTS:İS İT POSSİBLE TO TRANSPLANT SAFELY?, 2017
- peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma:A single center experience, 2017
- Kronik Myeloproliferatif Neoplazilerde Kalretikulin (CALR) mutasyonu, 2017
- Peripheral blood stem cell mobilization and collectionfrom elderly patients (≥65 years) with multiple myeloma: Asingle center experience, 2017
- HLA C1/C1 homozygosity decreases relapse rate afterallogeneic hematopoietic stem cell transplantation(Allo-HSCT) in acute myeloid leukemia (AML) patients, 2017
- Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible totransplant safely?, 2017
- HLA C1/C1 homozygosity decreases relapse rate after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in acute myeloid leukemia (AML) patients, 2017
- Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL), 2017
- Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients, 2017
- Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma, 2017
- Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma, 2017
- Gebelikte Kök Hücre Faktör (SCF) ve Granülosit Koloni Stimüle Edici Faktör (G-CSF) Düzeyleri ve in vitro Etkileri, 2017
- Maternal ve Fetal Serum Örneklerinde Hematopoietik Sitokinler Olan Kök Hücre Faktör (Stem Cell Factor=SCF) ve Granülosit Koloni Stimule Edici Faktör (G-CSF) Düzeylerinin ve in vitro Etkilerinin Karşılaştırılmalı Analizi., 2017
- Multiple Myeloma ‘da Risk Temelli Tedaviler, 2017
- Türkiye’den Çok Merkezli Erken Erişim Program Sonuçları: Daha Önce Yoğun Tedavi Almış Relaps/Refrakter Multipl Miyelom Hastalarında Daratumumabın Etkililik ve Güvenliliği, 2017
- Maternal ve Fetal Serum Örneklerinde Hematopoietik Sitokinler Olan Kök Hücre Faktör (Stem Cell Factor=SCF) ve Granülosit Koloni Stimule Edici Faktör (G-CSF) Düzeylerinin ve in vitro Etkilerinin Karşılaştırılmalı Analizi, 2017
- Propensity Score Matching Analysis to Evaluate the Comparative Effectiveness of Daratumumab versus Real-World Standard of Care Therapies for Patients with Heavily Pretreated and Refractory Multiple Myeloma, PSM Dara vs IMF Cohort Manuscript, 2017
- Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network., 2017
- NEXT GENERATION SEQUENCING METHODOLOGY FOR DETERMINING CYTOGENETIC RISK STATUS IN THE DARATUMUMAB PHASE 3 CASTOR AND POLLUX STUDIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA, 2017
- DAHA ÖNCE YOĞUN TEDAVİ ALMIŞ RELAPS/REFRAKTERMULTİPL MİYELOM HASTALARINDA DARATUMUMABINETKİLİLİK VE GÜVENLİLİĞİ, 2017
- Autologous Stem Cell Trnasplantation for Mantle Cell Lymphoma: A Single Center Exprience, 2017
- Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantationd for acute myeloid leukemia, 2017
- Allojeneik stem cell transplantation results in our myelodysplastic sydrome (MDS) patientes, 2017
- A single center experience With two decades of follow-up on patients With hairy cell leukemia, 2017
- Peripheral Blood Stem Cell Mobilization and collection from elderly patients 65 years with multipl myeloma: A , single center exprience, 2017
- Allegeneic Hematopoetic Stem Cell Trnasplantation (Allo-HSCT) in advanced age adults:Is it possible to transplant safely?, 2017
- Acute GVHD and unreated/haploidentical Trnasplants incrreses the incidence of hemorrhagic cystitis in Allo- HSCT Recipients, 2017
- Herpes SimplexVirus infection in patients after allogeneic hematopoetic stem cell transplantation, 2017
- Hematolojik Maligniteli Hastalarda Haploidentik Kök Hücre Nakillerinde Mezenkimal Kök Hücre Uygulaması.,
- Positive Impact of Chronic Graft Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients, 2015
- Treatment of multiple myeloma (including autologous SCT), 2017
- Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma, 2014
- Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?, 2014
- Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?, 2014
- Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values, 2014
- Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience, 2014
- Age, Cytopenia at Diagnosis and History of Hypertension are associated with Stem Cell Mobilization Failures Among Patients with Multiple Myeloma, 2015
- Generic (Bioequivalent) Melphalan Has Similar Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation, 2015
- The relapse in acute leukemia after the allogeneic hematopoetic stem cell transplantation: No approaches have been superior yet, 2015
- Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia, 2015
- Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT), 2015
- Upper and lower respiratory tract infections by respiratory viruses in adult recipients of allogeneic hematopoeitic stem cell transplantation (Allo-HSCT): Single center, 2015
- Erythrocytosis following allogeneic hematopoietic stem cell transplantation in six cases, 2015
- Different Doses of Anti-Thymocyte Globulin (ATG) in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation, 2015
- Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Single Centre Experience, 2015
- Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): A Single Center Experience, 2015
- HLA-A allele mismatch (7/8 or 9/10) is the second best option after 8/8 or 10/10 matched unrelated donors: An analysis on results from Turkish centers, 2015
- Are there any optimal cell doses for graft repopulation in the Bone Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations?, 2015
- Autologous Stem Cell Transplantation in Elderly Patients ( >=60 years) with Myeloma or Lymphoma: Single Center Experience, 2015
- Allogeneic Stem-Cell Transplantation for Hodgkin and non-Hodgkin Lymphoma: Single-center experience, 2015
- Is there an optimum CD3+T cell dose for donor lymphocyte infusion?, 2015
- Is it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation (HSCT) using Plasma Exchange (PE)?: A Single Center's Experience, 2015
- HLA TYPING OF A MULTITRANSFUSED SCID PATIENT: WHAT NGS CAN TELL US?, 2015
- ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)., 2015
- Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study., 2015
- Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients., 2015
- SUBCUTANEOUS BORTEZOMIB IS AS EFFECTIVE AND LESS NEUROTOXIC THAN INTRAVENOUS BORTEZOMIB: ANKARA University EXPERIENCE, 2015
- POST-AUTHORIZATION SAFETY OF LENALIDOMIDE plus DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EARLY SAFETY REPORT OF TURKISH PASS STUDY, 2015
- COMPARISON OF RED BLOOD CELL AND PLASMA DEPLETION EFFICIENCIES OF TWO METHODS FROM CORD BLOOD: AUTOMATED SEPAX (BIOSAFE) AND MANUAL CELLEFFIC (KANEKA), 2015
- FRONTLINE INDUCTION THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: THIRD INTERIM ANALYSIS OF THE MULTINATIONAL, OBSERVATIONAL EMMOS STUDY (NCT01241396), 2015
- ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA, 2015
- ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE, 2015
- SUBGROUP ANALYSIS BY PRIOR TREATMENT AMONG PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE, 2015
- ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone (ELd) vs Lenalidomide/Dexamethasone (Ld) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)-3-Year Safety and Efficacy Follow-up, 2016
- Clinical Characteristics and Frequency of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation, 2016
- Efficacy of High Dose Corticosteroid Premedication for the Prevention of Anti-thymocyte Globulin Related Side Effects, 2016
- Effect of Cytomegalovirus Reactivation on Prognosis After Allogeneic Transplantation for Acute Leukemia with Active Disease Conditioned with a Sequential Regimen and Anti-Thymocyte Globulin, 2016
- A CASE OF PROLONGED COAGULOPATHY CAUSED BY SUPERWARFARIN POISONING IN A WORKER, 2016
- THERAPEUTIC THROMBOCYTAPHERESIS: HIGHER PLATELET COUNTS SHOULD MATTER, 2016
- THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS: SINGLE CENTER EXPERIENCE, 2016
- THERAPEUTIC PLASMA EXCHANGE FOR THROMBOTIC MICROANGIOPATHY, 2016
- ARE AGE AND JAK2V617F MUTATION RELATED TO THROMBOSIS IN CHRONIC MYELOPROLIFERATIVE DISEASES?, 2016
- CD34 POSITIVE CELL COUNT DETECTED BY MULTI-COLOR FLOW CYTOMETRY (MFC) AFTER FIRST INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA (AML) EFFECTS ON SURVIVAL AND RELAPSE, 2016
- IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?, 2016
- OUR APPROACH TO HAIRY CELL LEUKEMIA HCL 31 YEARS OF EXPERIENCE,
- MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRE AND POST TRANSPLANT, 2016
- PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR, 2016
- Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR, 2016
- A benzamide derivative XT5 and imatinib combination induced apoptosis in Imatinib resistant K562 cell line, 2016
- PATIENT REPORTED OUTCOMES (PROS) OF MULTIPLE MYELOMA (MM) PATIENTS FROM THE PANORAMA-1 STUDY WHO HAVE RECEIVED AT LEAST TWO PRIOR REGIMENS INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT, 2016
- BEING OVERWEIGHT/OBESE PRIOR TO ALLOJENEIK HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IS RELATED TO BETTER OVERALL SURVIVAL (OS) AND DECREASED NON-RELASE MORTALITY, 2016
- Notch Ligandı Fibronektin Valproik Asit Nikotinamid ile Kordon Kanı Kök Hücrelerinin Ex Vivo Ekspansiyonu, 2016
- Computer Aided Drug Design Studies on Human Protease Activated Receptor 1 as Anticancer Target, 2016
- IS 23 Molecular Modeling and ADMET Studies of some heterocylics on Human Protease Activated Receptor 1 asAnticancer Target, 2016
- Regrafting For Primary and Secondary Graft Failure,
- ELOQUENT 2 Extended safety and efficacy follow up of the phase 3 randomized open label study of elotuzumab in combination with lenalidomide dexamethasone in patients with relapsed refractory multiple myeloma,
- Intensification Therapy with Bortezomib Melphalan Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma An Intergroup Multicenter Phase III Study of the European Myeloma Network EMN02 HO95 MM Trial,
- EX VIVO Expansion of Human Cord Blood Comparison of Enhancers,
- Ex Vivo Expansion of Human Umblical Cord Blood Hematopoietic Stem Cells HSC with Valproic Acid or Notch Ligand Fibronectin,
- Comparative Proteomic Analysis of Bone Marrow Plasma Cells By Using Mass Spectrometry Based Bottom up Proteomic Strategies, 2015
- Outcomes after Initial Relapse of Multiple Myeloma An International Myeloma Working Group Study, 2015
- Is Initial CD3 T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant, 2015
- Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation, 2015
- Eloquent 2 Update A Phase 3 Randomized Open Label Study of Elotuzumab in Combination with Lenalidomide Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma 3 Year Safety and Efficacy Follow up, 2015
- The Effect of Pre Transplant Psychological Well Being on Hematological Reconstitution Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients, 2015
- Analysis Of Outcomes Based On Response İn Patients With Relapsed Or Relapsed And Refractory Multiple Myeloma Treated With Panobinostat Or Placebo İn Combination With Bortezomib And Dexamethasone İn The Panorama 1 Trial Updated Analysis Based On Prior Treatment, 2015
- Final Analysis Of Overall Survival From The Phase 3 Panorama 1 Trial Of Panobinostat Plus Bortezomib And Dexamethasone Versus Placebo Plus Bortezomib And Dexamethasone İn Patients With Relapsed Or Relapsed And Refractory Multiple Myeloma, 2015
- Analysis Of Final Data From The Multinational Non Interventional Observational Emmos Study NCT01241396 İn Patients Pts With Multiple Myeloma MM İn Real World Clinical Practice, 2015
- Expression And İn Vitro Binding Of Protease Activated Receptor1 PAR1 With Novel Anti PAR1 Molecules Data On Fresh Myeloma Marrow Plasma Cells And Human Myeloma Cell Lines, 2015
- Expression and in Vitro Binding of Protease Activated Receptor1 PAR1 with Novel Anti PAR1 Molecules Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines, 2015
- Hepatitis B HBV Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide Containing Regimens A Single Center Experience, 2015
- Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs A predefined subgroup analysis of PANORAMA 1, 2015
- Upgrade Of FDG PET Response Following Autologous Stem Cell Transplantation Is Associated With Better Progression Free Survival Among Patients With Multiple Myeloma, 2015
- ASCO EDUCATIONAL BOOK, ISBN: EDBK_349643, 2022
- İmmünohematolojide Güncel Başlıklar, ISBN: 9786059160582, 2021
- Hematopoetik Kök Hücre Nakli Kitabı, ISBN: 9786058469914, 2019
- Türkiye Klinikleri Hematoloji Özel Dergisi, ISBN: 978-605-7505, 2018
- Türkiye Klinikleri Hematoloji Özel Dergisi, ISBN: 978-605-7505, 2018
- Hematolog, ISBN: 2146-6408, 2017
- Hematolog, ISBN: 2146-6408, 2017
- Hematolog, ISBN: 2146-6408, 2017
- İmmünoloji, ISBN: 978-605-89294-2-5, 2017
- İmmünoloji, ISBN: 978-605-89294-2-5, 2017
- Bone Marrow and Stem Cell Transplantation, ISBN: eISBN-10:1-59745-223-8, 2007
- Bone Marrow and Stem Cell Transplantation, ISBN: , 2014
- Bilim akademisi asosiye üyeliği, 1995
- Bilim akademisi asli üyeliği, 2004
- En başarılı araştırma ödülü, 2015
- Türk Hematoloji Derneği Bildiri Ödülü, 2016
- en başarılı Laboratuvar hematolojisi araştırma ödülü, 2017
- Best basic science abstract in multiple myeloma, 2017
- Türk Hematoloji Derneği Bildiri Ödülü, 2018
- Misafir profesörlük, 2018
- SÖZLÜ BİLDİRİ ÖDÜLÜ, 2019
- TÜRK HEMATOLOJİ DERNEĞİ SÖZLÜ BİLDİRİ ÖDÜLÜ, 2019
- 2020 YILI BİLİM ÖDÜLÜ, 2020
- En İyi Sözlü Bildiri Birincilik Ödülü, 2021
- En İyi Sözlü Bildiri Birincilik Ödülü, 2021
- 13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi En İyi Sözlü Bildiri İkincilik Ödülü, 2021
- YAŞLI AKUT MYELOİD LÖSEMİ TANILI HASTALARDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ:TEK MERKEZ DENEYİM, 2021
- AGRESİF LENFOMA TANILI FİT , YAŞLI HASTALARDA OTOLOG PERİFERİK KÖK HÜCRE:TEK MERKEZ DENEYİM, 2021
- En İyi Sunum Birincilik Ödülü, 2022
- Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of AntiCD38 Monoclonal Antibody Based Treatments for AL Amyloidosis, 2022
- Klinik Hematoloji Dalında Bildiri Ödülü, 2022
- Türk Hematoloji Derneği Bildiri Ödülü, 2022
